Published in Cancer Res on June 01, 1996
Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer (2000) 1.93
Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer (2001) 1.81
Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer (2004) 1.58
Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S-1-based chemotherapy: a multi-institute retrospective study. Gastric Cancer (2011) 1.52
S-1 in gastric cancer: a comprehensive review. Gastric Cancer (2003) 1.41
Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer (2008) 1.39
Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer (2005) 1.21
A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice. Gastric Cancer (2003) 1.14
Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer (2006) 1.14
Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity. Cancer Chemother Pharmacol (2009) 0.96
The role of S-1 in the treatment of gastric cancer. Br J Cancer (2008) 0.96
A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol (2015) 0.96
TAS-102, a novel antitumor agent: A review of the mechanism of action. Cancer Treat Rev (2015) 0.94
Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol (2013) 0.94
The oral fluorinated pyrimidines. Invest New Drugs (2001) 0.92
Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer (2005) 0.91
Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer. Gastric Cancer (2003) 0.91
A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-alpha. J Gastroenterol (2006) 0.90
Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma. Br J Cancer (2008) 0.90
Protective effect of the Japanese traditional medicine juzentaihoto on myelosuppression induced by the anticancer drug TS-1 and identification of a potential biomarker of this effect. BMC Complement Altern Med (2012) 0.89
Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study. Int J Clin Oncol (2007) 0.89
Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan. Invest New Drugs (2000) 0.89
Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer (2003) 0.88
Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis. World J Surg Oncol (2010) 0.87
A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. Br J Cancer (2006) 0.87
A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. Br J Cancer (2007) 0.86
New challenges and inspired answers for anticancer drug discovery and development. Jpn J Clin Oncol (2013) 0.86
Prognostic significance of dihydropyrimidine dehydrogenase expression in breast cancer. Br J Cancer (2002) 0.86
The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma. J Gastroenterol (2010) 0.86
Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604). Cancer Sci (2015) 0.85
Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. Br J Cancer (2009) 0.85
Challenge for a better combination with basic evidence. Int J Clin Oncol (2008) 0.85
The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Cancer Chemother Pharmacol (2010) 0.83
Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer. Cancer Chemother Pharmacol (2010) 0.83
A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer. Invest New Drugs (2008) 0.82
Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients. Ther Adv Med Oncol (2013) 0.82
Combination therapy of S-1 and CDDP for patients with colorectal cancer. J Cancer Res Clin Oncol (2007) 0.80
A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer. J Cancer Res Clin Oncol (2008) 0.80
A predictive factor for the response to S-1 plus cisplatin in gastric cancer. World J Gastroenterol (2010) 0.79
Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer. Gastric Cancer (2003) 0.79
Current directions in chemotherapy for colorectal cancer. J Gastroenterol (2006) 0.79
Global chemotherapy development for gastric cancer. Gastric Cancer (2016) 0.79
A phase I trial of S-1 with concurrent radiotherapy in patients with locally recurrent rectal cancer. Int J Clin Oncol (2012) 0.79
Efficacy of S-1 monotherapy for non-small cell lung cancer after the failure of two or more prior chemotherapy regimens. Oncol Lett (2010) 0.79
Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study. Gastric Cancer (2015) 0.79
Phase II trial of S-1 as third-line or further chemotherapy in patients with advanced non-small-cell lung cancer. Int J Clin Oncol (2014) 0.78
Long-term results of definitive concurrent chemoradiotherapy using S-1 in the treatment of geriatric patients with esophageal cancer. Onco Targets Ther (2016) 0.78
A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer. BMC Cancer (2015) 0.77
Tolerability of adjuvant chemotherapy with S-1 after curative resection in patients with stage II/III gastric cancer. Oncol Lett (2012) 0.77
Feasibility of adjuvant chemotherapy with S-1 consisting of a 4-week administration and a two-week rest period in patients with completely resected non-small cell lung cancer. Mol Clin Oncol (2012) 0.77
Combination therapy using oral S-1 and targeted agents against human tumor xenografts in nude mice. Exp Ther Med (2012) 0.77
A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer. Int J Colorectal Dis (2009) 0.77
Gastrointestinal toxicities of 5-fluorouracil increase the proportion of regulatory T cells in intestinal tract: advantages of alternate-day S-1 administration. Int J Clin Oncol (2015) 0.77
Usefulness of alternate-day administration of S-1 and leucovorin in a xenograft mouse model of colorectal cancer: a shorter drug-free interval leads to more efficient antitumor effects. Int J Clin Oncol (2014) 0.76
Hypoxia-inducible factor-targeting prodrug TOP3 combined with gemcitabine or TS-1 improves pancreatic cancer survival in an orthotopic model. Cancer Sci (2016) 0.76
Survivin expression can predict the effect of chemoradiotherapy for advanced lower rectal cancer. Int J Clin Oncol (2012) 0.76
UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction. Surg Today (2007) 0.76
Clinical outcomes of TS-1 chemotherapy for advanced and recurrent gastric cancer. J Korean Surg Soc (2011) 0.76
Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysis. Sci Rep (2016) 0.75
Current Development of Anti-Cancer Drug S-1. J Clin Diagn Res (2016) 0.75
Severe adverse effects of 5-fluorouracil in S-1 were lessened by haemodialysis due to elimination of the drug. NDT Plus (2008) 0.75
Successful chemotherapy with Carboplatin and s-1 for thymic carcinoma: a case report. Case Rep Oncol (2013) 0.75
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type. Oncol Lett (2011) 0.75
Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expression. Rare Dis (2016) 0.75
Effects of a concurrent chemoradiotherapy with S-1 for locally advanced oral cancer. Oncol Lett (2011) 0.75
Multicenter Phase II Study of a New Effective S-1 and Irinotecan Combination Schedule in Patients with Unresectable Metastatic or Recurrent Colorectal Cancer. Clin Med Insights Oncol (2013) 0.75
Phase I trial of oxaliplatin plus S-1 chemotherapy in patients with metastatic colorectal cancer. Oncol Lett (2010) 0.75
Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701. Jpn J Clin Oncol (2016) 0.75
Phase II multi-center clinical study on using S-1 to treat advanced breast cancer after resistance to anthracycline and taxane drugs in Chinese patients. Int J Clin Exp Med (2015) 0.75
Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706). Cancer Sci (2015) 0.75
Effect of celecoxib combined with chemotherapy drug on malignant biological behaviors of gastric cancer. Int J Clin Exp Pathol (2014) 0.75
Development and validation of a HPLC-MS/MS method with electrospray ionization for quantitation of potassium oxonate in human plasma: Application to a pharmacokinetic study. Exp Ther Med (2013) 0.75
S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy in Chinese patients with nonsmall-cell lung cancer: A multicentre randomized controlled trial. Medicine (Baltimore) (2016) 0.75
Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective. Ther Adv Med Oncol (2013) 0.75
Combination therapy with S-1 and interferon-α in hepatocellular carcinoma patients with lung metastasis. Mol Clin Oncol (2014) 0.75
Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy. Invest New Drugs (2002) 0.75
Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001. Int J Clin Oncol (2016) 0.75
Successful Outcome of Low-Dose S-1 Used to Treat Buccal Squamous Cell Carcinoma. Case Rep Oncol Med (2017) 0.75
Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine. Intern Med (2017) 0.75
Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer. Jpn Dent Sci Rev (2016) 0.75
Gimeracil enhances the antitumor effect of cisplatin in oral squamous cell carcinoma cells in vitro and in vivo. Oncol Lett (2017) 0.75
S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). Int J Clin Oncol (2016) 0.75
Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study. Gastric Cancer (2003) 0.75
Current topics of S-1 at the 74th Japanese Gastric Cancer Congress. Gastric Cancer (2003) 0.75
Levels and expressions of orotate phosphoribosyltransferase in gastric carcinoma and normal gastric mucosa tissues. Gastric Cancer (2007) 0.75
The transcriptional landscape of the mammalian genome. Science (2005) 37.63
High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med (2001) 12.49
A two-component system that regulates an osmosensing MAP kinase cascade in yeast. Nature (1994) 9.77
Randomization of left-right asymmetry due to loss of nodal cilia generating leftward flow of extraembryonic fluid in mice lacking KIF3B motor protein. Cell (1998) 8.16
Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell (2000) 7.87
Yeast HOG1 MAP kinase cascade is regulated by a multistep phosphorelay mechanism in the SLN1-YPD1-SSK1 "two-component" osmosensor. Cell (1996) 6.87
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A (2001) 6.70
Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J (1998) 6.65
Enzymatic methods for the determination of small quantities of isomeric chondroitin sulfates. J Biol Chem (1968) 6.28
Purification and properties of bacterial chondroitinases and chondrosulfatases. J Biol Chem (1968) 5.66
A polyadenylate binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells. Cell (1991) 5.65
Activation of yeast PBS2 MAPKK by MAPKKKs or by binding of an SH3-containing osmosensor. Science (1995) 5.49
Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs (1996) 5.45
Complete primary structure of a heterodimeric T-cell receptor deduced from cDNA sequences. Nature (1984) 5.19
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood (2001) 5.17
Osmotic activation of the HOG MAPK pathway via Ste11p MAPKKK: scaffold role of Pbs2p MAPKK. Science (1997) 5.02
Mesoscale iron enrichment experiments 1993-2005: synthesis and future directions. Science (2007) 4.92
Increased ratio of targeted to random integration after transfection of chicken B cell lines. Cell (1991) 4.65
Developmental regulation of T-cell receptor gene expression. Nature (1985) 4.53
Targeted disruption of mouse conventional kinesin heavy chain, kif5B, results in abnormal perinuclear clustering of mitochondria. Cell (1998) 4.35
Sister chromatid exchanges are mediated by homologous recombination in vertebrate cells. Mol Cell Biol (1999) 4.20
Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs. Mol Cell Biol (2001) 4.19
A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell (1998) 3.89
Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet (1997) 3.89
Regulated nucleo/cytoplasmic exchange of HOG1 MAPK requires the importin beta homologs NMD5 and XPO1. EMBO J (1998) 3.87
Initiation of the DNA replication of bacteriophage lambda in Escherichia coli K12. J Mol Biol (1977) 3.70
Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. Cell (2001) 3.49
Structure, organization, and somatic rearrangement of T cell gamma genes. Cell (1985) 3.49
A third rearranged and expressed gene in a clone of cytotoxic T lymphocytes. Nature (1984) 3.46
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood (1999) 3.46
Signal transduction in neuronal migration: roles of GTPase activating proteins and the small GTPase Cdc42 in the Slit-Robo pathway. Cell (2001) 3.44
Activation of the c-myc gene by translocation: a model for translational control. Proc Natl Acad Sci U S A (1983) 3.36
Reduced X-ray resistance and homologous recombination frequencies in a RAD54-/- mutant of the chicken DT40 cell line. Cell (1997) 3.23
Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem (1995) 3.20
A family of receptor-linked protein tyrosine phosphatases in humans and Drosophila. Proc Natl Acad Sci U S A (1989) 3.18
Differential usage of three exons generates at least five different mRNAs encoding human leukocyte common antigens. J Exp Med (1987) 3.14
Ablation of XRCC2/3 transforms immunoglobulin V gene conversion into somatic hypermutation. Nature (2001) 3.09
Complete primary structures of the E beta chain and gene of the mouse major histocompatibility complex. Proc Natl Acad Sci U S A (1983) 3.09
Classification criteria for polymyositis and dermatomyositis. J Rheumatol (1995) 3.08
Visualization of neurogenesis in the central nervous system using nestin promoter-GFP transgenic mice. Neuroreport (2000) 3.04
Distinct functional roles of the two intracellular phosphatase like domains of the receptor-linked protein tyrosine phosphatases LCA and LAR. EMBO J (1990) 2.94
Nucleotide sequence of the tobacco mosaic virus (tomato strain) genome and comparison with the common strain genome. J Biochem (1984) 2.93
Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus. Nature (1984) 2.93
ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nat Cell Biol (2000) 2.90
Identification of the transcriptional suppressor sof-1 as an alteration in the spo0A protein. J Bacteriol (1985) 2.89
Determination of aminosugar linkages in glycolipids by methylation. Aminosugar linkages of ceramide pentasaccharides of rabbit erythrocytes and of Forssman antigen. Arch Biochem Biophys (1973) 2.87
Organization and expression of the dnaJ and dnaK genes of Escherichia coli K12. Mol Gen Genet (1978) 2.81
Heterothallic Behavior of a Homothallic Strain in Saccharomyces Yeast. Genetics (1958) 2.81
Structural diversity and evolution of human receptor-like protein tyrosine phosphatases. EMBO J (1990) 2.81
Activation of the yeast SSK2 MAP kinase kinase kinase by the SSK1 two-component response regulator. EMBO J (1998) 2.74
A new member of the immunoglobulin superfamily that has a cytoplasmic region homologous to the leukocyte common antigen. J Exp Med (1988) 2.74
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene (2000) 2.73
Coding visual images of objects in the inferotemporal cortex of the macaque monkey. J Neurophysiol (1991) 2.70
Mre11 is essential for the maintenance of chromosomal DNA in vertebrate cells. EMBO J (1999) 2.66
Regulation of the Saccharomyces cerevisiae HOG1 mitogen-activated protein kinase by the PTP2 and PTP3 protein tyrosine phosphatases. Mol Cell Biol (1997) 2.65
A co-operative numerical analysis of rapidly growing mycobacteria. J Gen Microbiol (1972) 2.63
Limited diversity of the rearranged T-cell gamma gene. Nature (1985) 2.58
Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg (2011) 2.57
Molecular cloning and expression of a member of the aquaporin family with permeability to glycerol and urea in addition to water expressed at the basolateral membrane of kidney collecting duct cells. Proc Natl Acad Sci U S A (1994) 2.54
Cloning and nucleotide sequence of phoP, the regulatory gene for alkaline phosphatase and phosphodiesterase in Bacillus subtilis. J Bacteriol (1987) 2.52
High efficiency transformation of maize (Zea mays L.) mediated by Agrobacterium tumefaciens. Nat Biotechnol (1996) 2.43
Regulation of tissue-specific alternative splicing: exon-specific cis-elements govern the splicing of leukocyte common antigen pre-mRNA. EMBO J (1989) 2.41
The Rad51 paralog Rad51B promotes homologous recombinational repair. Mol Cell Biol (2000) 2.39
Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res (1993) 2.37
Unusual organization and diversity of T-cell receptor alpha-chain genes. Nature (1985) 2.36
Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia (1998) 2.35
Dexamethasone in the treatment of acute mountain sickness. N Engl J Med (1989) 2.31
Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. Proc Natl Acad Sci U S A (1998) 2.31
Scc1/Rad21/Mcd1 is required for sister chromatid cohesion and kinetochore function in vertebrate cells. Dev Cell (2001) 2.30
Genetic analysis of two genes, dnaJ and dnaK, necessary for Escherichia coli and bacteriophage lambda DNA replication. Mol Gen Genet (1978) 2.30
Nucleotide sequence of the primary origin of bacteriophage T7 DNA replication: relationship to adjacent genes and regulatory elements. Proc Natl Acad Sci U S A (1980) 2.30
Two-component signal transducers and MAPK cascades. Trends Biochem Sci (1997) 2.29
Two acyl-coenzyme A oxidases in peroxisomes of the yeast Candida tropicalis: primary structures deduced from genomic DNA sequence. Proc Natl Acad Sci U S A (1986) 2.24
Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun (1997) 2.22
Fate of coronary aneurysms in Kawasaki disease: serial coronary angiography and long-term follow-up study. Am J Cardiol (1982) 2.22
Homologous recombination, but not DNA repair, is reduced in vertebrate cells deficient in RAD52. Mol Cell Biol (1998) 2.19
Evaluation of topical pharyngeal anesthesia for upper endoscopy including factors associated with patient tolerance. Gastrointest Endosc (2001) 2.19
Inhibition of GABAA synaptic responses by brain-derived neurotrophic factor (BDNF) in rat hippocampus. J Neurosci (1997) 2.18
Mapping of genes determining nonpermissiveness and host-specific restriction to bacteriophages in Bacillus subtilis Marburg. Mol Gen Genet (1979) 2.17
Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A (1999) 2.17
The controlling role of ATM in homologous recombinational repair of DNA damage. EMBO J (2000) 2.17
Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling. Immunity (2000) 2.16
A rare case of bilateral supernumerary teeth in the mandibular incisors. Br Dent J (1998) 2.16
The natural history of herniated nucleus pulposus with radiculopathy. Spine (Phila Pa 1976) (1996) 2.16
Protein phosphatase 2Calpha inhibits the human stress-responsive p38 and JNK MAPK pathways. EMBO J (1998) 2.11
Yeast Cdc42 GTPase and Ste20 PAK-like kinase regulate Sho1-dependent activation of the Hog1 MAPK pathway. EMBO J (2000) 2.10
Expression levels of DNA methyltransferase genes do not correlate with p15INK4B gene methylation in myelodysplastic syndromes. Leukemia (2003) 2.06
Subcutaneous release of trigger thumb and fingers in 210 fingers. J Hand Surg Br (1990) 2.05
Analysis of local and wide-field movements in the superior temporal visual areas of the macaque monkey. J Neurosci (1986) 2.03
Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet (2000) 2.02
Nucleotide sequence of the Bacillus subtilis phoR gene. J Bacteriol (1988) 2.02
Mutations in a protein tyrosine phosphatase gene (PTP2) and a protein serine/threonine phosphatase gene (PTC1) cause a synthetic growth defect in Saccharomyces cerevisiae. Mol Cell Biol (1993) 2.01
Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol (1988) 2.01
Prenatal DNA diagnosis of a single-gene disorder from maternal plasma. Lancet (2000) 2.01
Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci U S A (2004) 1.99
Isolation and characterization of transposon mutants of Staphylococcus epidermidis deficient in capsular polysaccharide/adhesin and slime. Infect Immun (1993) 1.99
Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3. Biochem Biophys Res Commun (1997) 1.97